Participation in prestigious medical and surgical research trials helps patients gain access to promising new treatments and technology. The research team participates in industry-sponsored and investigator-initiated research studies. The team works closely to incorporate research findings into the comprehensive care to improve patient outcomes.
Pulmonary Arterial Hypertension Trials
Actelion Pharmaceutical ACT-293987/ Griphon 2 Double-Blind Protocol AC- 065A302 — multicenter, double-blind, placebocontrolled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension.
Actelion Pharmaceutical Open-label/ Protocol AC-065A303 — a long-term singlearm open-label study to assess the safety and tolerability of ACT293987 in patients with pulmonary arterial hypertension.
Actelion Pharmaceutical Prospect Registry 1-Year Study/ RTS-Epoprostenol (Flolan) Protocol AC-066A501 — a registry to prospectively describe use of Epoprostenol for injection ("RTSEpoprostenol") in patients with pulmonary arterial hypertension.
Gilead Pharmaceutical Ambition Study — a Phase III/IV randomized, multicenter study of first-line Ambrisentan and Tadalafil combination therapy in subjects with pulmonary arterial hypertension.
Dr. Klinger T2 TRIAL — Phase IV randomized placebo-controlled trial of Treprostinil infusion combined with oral Tadalafil or placebo in pulmonary arterial hypertension.
United Therapeutics — Post-Marketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso® (Treprostinil) Inhalation Solution.
Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program.
Geno Pharmaceuticals Phase 2, open-label, dose – escalation study in subjects with pulmonary arterial hypertension, (PAH, WHO Group 1) and pulmonary hypertension secondary to idiopathic pulmonary fibrosis, (PH-IPF WHO Group 3) using inhaled Nitrosyl.
United Therapeutics, Inc. Open-Label Extension Trial of UT-15C SR (Oral Treprostinil) in Subjects with Pulmonary Arterial Hypertension.
[ top ]
Idiopathic Pulmonary Fibrosis Trials
Immune Works, Inc. Phase 1, Open-Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients with Idiopathic Pulmonary Fibrosis.
Intermune, Inc. Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
[ top ]
Lung Transplant Clinical Trials
Blood Biomarkers of Primary and Chronic Graft Dysfunction — NIH-sponsored study.
[ top ]